SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Subcutaneous foslevodopa/foscarbidopa initiation in a Parkinson's day-clinic - a suitable setting to ensure treatment efficacy, tolerability and psychosocial adaption.

Front Aging Neurosci · 2025-09-10

DOI: 10.3389/fnagi.2025.1619850PMID: 41001152

Open accessresearch-article; Journal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

BackgroundSubcutaneous foslevodopa/foscarbidopa (LDp/CDp) has expanded the treatment options in advanced Parkinson's disease (aPD). However, the most appropriate therapeutic setting for therapy implementation is not clear.ObjectiveTo present a concept for LDp/CDp therapy implementation in a Parkinson's day-clinic and efficacy and safety outcome data from patients under the new therapeutic regimen.MethodsRetrospective clinical data were collected from the first 24 patients with aPD who were initiated on LDp/CDp treatment at the Hamburg Parkinson's day-clinic. Outcome parameters were analyzed in terms of motor symptoms (MDS -UPDRS II-IV), safety aspects and effects on patients' quality of life (PDQ-39).ResultsThe concept of the Parkinson's Day-clinic enabled the successful implementation of LDp/CDp therapy in patients with advanced Parkinson's disease (aPD). It provided individualized medical supported via neurologists, specialized nurses and therapists and thus facilitated the transition from clinic-based care to home-based support. Compared to previous optimized oral treatment, the application of LDp/CDp significantly reduced motor complications such as dyskinesias and motor fluctuations by 53% on the MDS-UPDRS IV (p = 0.0094). Motor function improvements were paralleled by a numerical increase in activities of daily living scores (MDS-UPDRS II) and improvement in long-term mobility (PDQ-39 mobility subscale), suggesting potential benefits in daily functioning and perceived mobility.ConclusionThe value of our data is limited by its retrospective design and small sample size. However, the data suggest that a proper day-clinic setting enables the successful implementation of subcutaneous LDp/CDp therapy with improvement of motor functions and reduction of side effects. It also ensures the necessary intensive medical support and offers comprehensive device-related and psychosocial guidance for both patients and caregivers.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.